Gruppo Parpas is an Italian company that designs and manufactures high-speed milling machines and large gantry-type machining centers.

Gruppo Parpas

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.

Metric
Company Name	Gruppo Parpas	Camurus AB (publ)
Symbol		CAMX
MSH ID	COM:GRUPPOPARPAS	COM:CAMURUS
Market	PRIVATE	STOCKS
Sector	Capital Goods & Industrials	Healthcare
Industry	Industrial Machinery Manufacturing	Biotechnology
Country	IT	SE
Stage
Employee Count		218
Website	gruppoparpas.com	camurus.com
LinkedIn
Founders

Metric
Market Cap		3.45B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue		157.08M
Revenue (LTM)
Revenue (NTM)
Gross Profit		144.61M
EBITDA		49.99M
Operating Income		48.71M
Net Income		39.47M
EPS		0.71
Diluted EPS		0.69
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.95
Operating Profit Margin		0.31
EBITDA Margin		0.32
Net Profit Margin		0.25
Return on Equity		0.33
Return on Assets		0.24
Return on Capital Employed		0.35

GRUP

COM:GRUPPOPARPAS

Gruppo Parpas

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		63.91
P/B Ratio		19.74
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		26.29
EV Multiple		153.13

Metric
Days Sales Outstanding
Days Payables Outstanding		231.09
Days Inventory Outstanding		378.15
Operating Cycle		455.94
Cash Conversion Cycle		266.55
Asset Turnover		0.96

Metric
Operating Cash Flow		55.53M
Free Cash Flow		54.60M
Cash Flow to Debt		62.84
Operating Cash Flow/Sales		0.41
Free Cash Flow Yield		0.02

Metric
Cash & Equivalents		108.86M
Accounts Receivable		-8.10M
Inventory		9.24M
Goodwill
Debt to Capitalization		0.02
Debt to Assets		0.01
Current Ratio		5.05
Quick Ratio		7.39

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.03
R&D to Revenue		0.34
SG&A to Revenue		0.03